ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

Lin, Anqi; Fang, Jianbo; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*南方医科大学; 郑州大学; 1
Journal of Inflammation Research2022DOI: 10.2147/JIR.S379016Journalof
8阅读
引用收藏
分享

摘要

Purpose: The advent of immune checkpoint inhibitors (ICIs) is a revolutionary breakthrough. However, without the selection of a specific target population, the response rate of ICI therapy in lung adenocarcinoma (LUAD) is low, so a clinical challenge has arisen in effectively using biomarkers to determine which patients can benefit from ICI therapy. Methods: In this study, patients were divided according to whether or not nonsynonymous mutations were present in the BCR signaling pathway, and univariate and multivariate Cox regression models were established based on a LUAD cohort treated with ICIs (Miao-LUAD). Then the relationship between the mutation status of the BCR signaling pathway and the prognosis of immunotherapy was examined. Finally, data from The Cancer Genome Atlas (TCGA) LUAD cohort, the Rizvi-LUAD, the Samstein-LUAD, and the Zhujiang Hospital of Southern Medical University LUAD (Local-LUAD) cohort were combined, and the mutation panorama, immunogenicity, tumor microenvironment (TME) and pathway enrichment analysis between the BCR signaling pathway mutant group (BCR signaling MUT) and the BCR signaling pathway wild group (BCR signaling WT) were comprehensively compared. Results: It was found that, compared with the BCR signaling WT, the BCR signaling MUT had a significantly improved progressiondamage response signaling mutations), and anti-tumor immune microenvironment. Conclusion: These results revealed that the mutation state of the BCR signaling pathway has potential as a biomarker to predict the efficacy of ICIs in LUAD.

学科与关键词

关键词
non -small cell lung cancerB cell receptorimmune checkpoint inhibitorbiomarkermicroenvironment
相关
加载中…
  • TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Lin, Anqi; Zhang, Hongman; Meng, Hui; Deng, Ze; Gu, Tianqi; Luo, Peng*; Zhang, Jian*Frontiers in Immunology, 2021, 12: 667875.被引 8
  • Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
    Lin, Anqi; Xu, Wentao; Luo, Peng*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 721181.被引 5
  • ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Zhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Inflammation Research
发表日期
2022
卷期
第 15 卷
DOI
10.2147/JIR.S379016Journalof
期刊等级
3区
成果收录
SCIE

作者

  • L

    Lin, Anqi (第一作者)

    southern med univ

  • F

    Fang, Jianbo

    southern med univ

查看全部 6 位作者收起作者
  • C

    Cheng, Quan

  • L

    Liu, Zaoqu

    1 · zhengzhou univ

  • L

    Luo, Peng (通讯)

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417